Vaginal estrogen for UTI prevention

Obstetrics & Gynaecology · Urology
Recurrent urinary tract infections (UTIs) are common in postmenopausal women and are frequently associated with estrogen deficiency and genitourinary syndrome of menopause (GSM). Reduced estrogen levels lead to vaginal and urethral epithelial thinning, decreased glycogen availability, and alterations in the vaginal microbiota, including reduced Lactobacillus colonisation and increased vaginal pH. These changes favour the colonisation and growth of uropathogens, particularly Escherichia coli, increasing susceptibility to recurrent infections. Vaginal estrogen therapy helps restore the urogenital environment and is an established preventive approach for recurrent UTIs in appropriate postmenopausal women. However, its effectiveness relies on the appropriate selection of formulation, correct application technique, and adherence to the recommended treatment schedule.[1]Role of vaginal estrogen in UTI preventionRestoration of vaginal epithelium: Local estrogen improves epithelial thickness and maturation, supporting the natural protective barrier of the vagina and urethraImprovement in vaginal microbiota: Estrogen promotes glycogen accumulation within vaginal epithelial cells, supporting Lactobacillus growth and helping restore the acidic vaginal environmentReduction in uropathogen colonization: A healthier vaginal microbiota and lower vaginal pH may reduce colonization by organisms associated with recurrent UTIsImprovement in genitourinary symptoms: Vaginal estrogen can also relieve vaginal dryness, irritation, dyspareunia, and urinary symptoms associated with GSMVaginal estrogen formulations and application techniquesVaginal cream: The prescribed amount is measured using the supplied applicator and inserted gently into the vagina. Cream may also be applied to the vaginal opening when external vulvovaginal symptoms are present, according to the product instructionsVaginal tablets or inserts: The tablet or insert is placed into the vagina using the supplied applicator or clean fingers, depending on the formulation. It should be positioned comfortably within the vagina rather than forced against resistanceVaginal rings: The flexible ring is compressed and inserted into the vagina, where it remains in place and releases estrogen gradually over the specified treatment period. Correct positioning and adherence to replacement instructions are importantApplication consistency: Patients should follow the prescribed loading and maintenance schedule because dosing frequency varies between formulations. Missed doses should be managed according to the product instructions rather than compensated for by doubling the next dosePractical considerations for effective applicationPatients should wash their hands before and after applying vaginal estrogen to reduce contamination and maintain hygieneApplicators should be cleaned or disposed of according to the manufacturer's instructions, depending on whether they are reusable or single-useVaginal estrogen is generally administered at bedtime when possible, particularly with creams or inserts, to minimize leakage and improve comfortPatients should be advised that local improvement may take several weeks and that continued maintenance treatment may be necessary to preserve the benefitsVaginal estrogen should not be used as a substitute for appropriate evaluation and treatment of an active UTIClinical considerations and safetyClinical considerationPractical approachRecurrent UTI without active infectionConsider vaginal estrogen as a preventive strategy in appropriate postmenopausal patientsVaginal dryness or irritationSelect a formulation that the patient can apply comfortably and consistentlyDifficulty using an applicatorConsider an alternative formulation, such as a vaginal ring or insertUnexplained vaginal bleedingInvestigate the cause before continuing or initiating treatmentHistory of estrogen-sensitive malignancyIndividualize treatment decisions and consider specialist consultationPersistent urinary symptomsEvaluate for active infection, other urinary conditions, or alternative causesConclusionEstrogen deficiency during menopause contributes to urogenital changes, including vaginal atrophy and an increased susceptibility to recurrent UTI. Local vaginal estrogen therapy, unlike systemic estrogen therapy, has demonstrated benefits in reducing recurrent UTIs in postmenopausal women. Its effectiveness depends on appropriate formulation selection, correct application or insertion technique, adherence to the recommended treatment schedule, and adequate patient education. Individualised treatment based on clinical symptoms, patient preferences, and contraindications is essential to optimise outcomes. Appropriate evaluation of persistent or recurrent urinary symptoms is also important to identify underlying conditions and guide further management.[2]Reference(s):1. Ghasoub R, Mackay W, Shepherd A. Vaginal Estrogen for Urinary Tract Infection Prevention: A Narrative Review of Evidence, Guidelines, and Regulatory Gaps. Gynecol Obstet Invest. Published online June 30, 2026. doi:10.1159/000553344. https://pmc.ncbi.nlm.nih.gov/articles/PMC13456662/2. Stanton A, Mowbray C, Lanz M, et al. Topical Estrogen Treatment Augments the Vaginal Response to Escherichia coli Flagellin. Sci Rep. 2020;10(1):8473. Published 2020 May 21. doi:10.1038/s41598-020-64291-y. https://pmc.ncbi.nlm.nih.gov/articles/PMC7242342/.